Exact Sciences' (EXAS) legacy screening business sees a decline in revenues in Q2 earnings.
Zacks · 07/31 16:13
Wall Street Breakfast: Big Beats From Big Tech
Seeking Alpha · 07/31 11:04
Exact Sciences Beats Q2 Estimates Despite a COVID-19 Drag
Exact Sciences (NASDAQ: EXAS) hasn't fired up investors so far in 2020 like it did last year. The good news is that Exact Sciences' management team said that there were signs of improvement in the quarterly conference call in May. Here are the highlights fro
Motley Fool · 07/31 10:38
Thermo Fisher Long Case: Trajectory Is Clear, Buy On Value
Seeking Alpha · 07/31 04:00
Exact Sciences Q2 Cologuard revenue down 34% due to pandemic disruptions